Novartis spinout’s first anti-aging PhIII is a flop, so now they’ll turn to Parkinson’s challenge as shares wilt
Novartis spinout resTORbio is grappling with the collapse of its lead clinical program this morning — an anti-aging R&D failure that will badly damage their rep in the field.
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.